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monitor. Arrhythmias were automatically detected and the tracings transmitted
by phone to a secure server for heart rate (HR) analysis.This study main objec-
tive was to evaluate the detection of 6 different kinds of arrhythmias including
supraventricular tachycardia (TC), atrial fibrillation (AF)/flutter, pause >3 sec-
onds, atrioventricular block, ventricular TC or inappropriate sinusal TC
Results: 167 patients with sinus rhythm. 39% men and 61% women, mean
age of 64 years old. 9% had already experienced a stroke and 7% suffered cor-
onary disease. 35% were taking an anti-arrythmic and 17% were taking anti-
coagulant. CHADS2Vasc2 = 2.
Monitoring lasted 11 days, 11 hours per day, 248 ECG were transmitted.
Results:
 – absence of abnormality (44%)
 – onset of AF (31%) 
 – discovery of regular sinusal TC (25%) treated with heart rate control
medications 
Screening and early detection of AF is one of the strategy main priorities
to optimise anti-arrhythmia and anticoagulant treatment in real time. Early
results show that 4 patients have an indication of implant placement and 3 for
radiofrequency ablation. Both system and method are a quick and interesting
solution to data transfer between medical experts and local family practitio-
ners in order to take the most appropriate decisions
Conclusion: A long-term single-lead monitoring in detection of arrhythmia
events on referred patients for ecg ambulatory monitoring is a simple method.
The quality of life of rural population and retired people who require medical
attention without moving could be significantly improved in term of diagnosis,
treatment and drug prescriptions to prevent stroke (figure above).
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Purpose: Remote monitoring (RM) is accepted as a reliable option to stan-
dard follow-up (sFU) for ICD, but little is known about its additional value for
implantable loop recorders (ILR).
Methods: We analyzed clinical outcomes and device-related data of
69 patients (pts) with ILR followed in two centers. Pts were implanted with
Medtronic Reveal XT and provided with Carelink. FU started after hospital
discharge. Manual RM transmissions (RMt) were performed every 2 weeks,
or in case of symptoms, with at least one sFU /year. In emergency cases, pts
were invited for in-hospital visits.
Results: We enrolled 69 pts (42% male, 64±14 years old). 90% were
implanted for syncope or lipothymia. 26% suffered of a cardiopathy, and 42% pre-
sented an abnormal EKG. During 14±9 months, we noted 22±19 RMt and 2±1
sFU visit per patient. 67 had symptoms RMt (5±6 per patient) and 67,65 and 66
pts experienced 2±3, 2213±4132, 82±144 RMt episodes classified as VT, brady-
cardia and asystole. Within the 54 pts with RMt judged as reliable by the physi-
cian, rate of episodes was respectively 5±7, 2±3, 10±16 and 47±83 for symptoms,
VT, bradycardia and asystole. For 15 pts, ILR data were judged as not reliable
(oversensing 20%, undersensing 47%, inability to RMt 33%). It led to
9772±15105 episodes per patient, mostly due to R wave undersensing. 27 pts
experienced significant symptoms, and RMt led to cardiac diagnosis in 14 pts (11
pacemaker implantations). 13 pts experienced syncope without significant abnor-
mality on RMt, leading to a diagnosis of non-cardiac disease. Rate of diagnosis
(cardiac and non- cardiac) was 41% in the reliable group, and 47% in « non-reli-
able » group mostly due to symptoms acquired with RMt.
Conclusion: In a dual center observational study, RM can be an effective
method of FU for ILR recipients and evaluated to reduce unnecessary sFU.
Symptoms captured by RMt allow rapid diagnostic assessment, even in pres-
ence of sensing issues.
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Background: Renal insufficiency (RI) is frequent in patients eligible for
cardiac resynchronization therapy (CRT) and may be worsened by the use of
contrast agents. 
Objective: We sought to determine the feasibility of CRT implantation
without contrast injection in patients with contraindication to iodine.
Methods: Patients eligible for CRT and presenting with RI were prospectively
included (non-contrast NC group). A contemporary control group (CG) of CRT
patients with contrast injection was used for comparison. An over-the-wire coro-
nary sinus (CS) lead with angled distal tip was selected for this “blind harpooning”
technique. A lateral branch was targeted at first intention in a left anterior oblique
fluoroscopic view. In case of failure, a contrast injection was then allowed if no
lateral branch was found with the « blind » strategy. 
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Results: 9 patients in the NC group were included (78±8 y). Serum
creatinine was 204±72μmol/L (clearance 34.2±17ml/min). CG included
10 patients (69,8±7 y, serum creatinine 98.7±23μmol/L). CRT implantation
was successful in 8/9 patients (88.9%) without contrast injection. Patient 9
was finally implanted with CS opacification after failure of the NC technique.
Mean procedure time and fluoroscopy time were similar in the two groups:
146±26 in the NC group versus 157±25 min (p = 0.34) and 24.8±15 in the NC
group versus 24.5±20 min (p = 0.96) respectively. Mean CS lead implantation
time was 45±21 (NC group) versus 37±12 min (p = 0.24). No major proce-
dure-related complications were observed in both groups.
Conclusion: CRT implantation is feasible in the majority of the cases
(88.9%) without contrast injection and without lengthening procedure time in
patients with RI. 
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Objective: Atrial fibrillation (AF) is a common arrhythmia associated with
increased risk of thromboembolic events or other complications. The French ran-
domized, multicenter, SETAM trial assessed the impact of the home monitoring
(HM) technology on detection and treatment of supra-ventricular arrhythmia
(SVA).
Methods: Patients (pts) implanted with a dual chamber pacemaker were
enrolled in the study at hospital discharge if they had a sinusal rhythm at enroll-
ment, no antiarrhythmic, anticoagulant or dual-antiplatelet therapy, and if they had
a CHA2DS2-VASc score of 2 or more. The pts were randomly assigned to an
active group (Act Gp), followed by Biotronik HM, or a control group (Cont Gp)
without HM surveillance. The time from implantation to the first SVA-related
intervention was compared between the 2 groups (primary endpoint).
Results: A total of 595 pts (mean age = 79±8 y.o, 63% male, mean
CHA2DS2-VASc score = 3.7±1.2) were followed during 12.8±3.3Mo. The
most prevalent co-morbidities were hypertension (82% pts), diabetes (29%)
and vascular disease (24%). Implantation indications were atrio-ventricular
blocks in 77% of pts, sinus node disease in 20% and others in 3%.The global
SVA incidence was 25% (29% in the Act Gp vs 22% in the Cont Gp, p=ns).
A therapy (drugs or ablation) was instituted for 49/291 pts (17%) in the Act
Gp vs 43/304 pts (14%) in the Cont Gp (p=ns). The median time from implan-
tation to the first therapy for SVA was 114 [44; 241] days in the Act Gp vs
224 [67; 366] days in the Cont Gp, representing a median gain of 110-days in
SVA management (50% reduction, p=0.01). Over these 92 pts, 54 had AF
(59%) and 38 had atrial flutter or tachyarrhythmia (41%). Anticoagulation was
initiated in 80% of pts and antiarrhythmic drugs in 55%.
Conclusion: The SETAM study demonstrated that HM allows earlier detection
and treatment of SVA in pacemaker pts. The next step is to report how early
detection of SVA with HM can possibly improve the patients clinical outcome.
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Aim: to evaluate routine French implanters strategy in device replacement
in patients under anticoagulation for atrial Fibrillation (AF pts). 
Method: A questionnaire was e-mailed to 140 French implanters.
Results: 102 aswers were obtained. In AF patients, admission is on day of
procedure D0 (10%) or D-1(80%) whether pts are on vitamine K antagonist
(VKA) or New Oral AntiCoagulant (NOAC). In AF pts under VKA, only 4%
bridge to Low Weight Heparine (LWH) or Unfractionated Heparine (UH)
while treatment is interrupted without substitution (wos) by 61% and
continued without interruption by 32%. In AF pts under NOAC, only 5%
bridge to UH or LWH while treatment is interrupted on D-3 (13%), D-2(25%),
D-1(44%). When interrupted, NOAC are resumed at D0 (23%), D+1(54%),
D+2(10%), D+3(3%).
Conclusions: Most of implanters hospitalize AF pts at D-1 of replacement
procedure. Short discontinuation (VKA, NOAC) or uninterruption (VKA) is
prefered to bridging strategy.
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Background: Approximately 1% of the adult population have heart failure
with reduced ejection fraction. Since the 1980s, therapeutic advances in this
field have been significant, particularly through the development of cardiac
resynchronization therapy (CRT). However, transvenous implantation of the
left ventricular (LV) lead is unsuccessful in 5 – 15% of patients. For this
group, surgical placement of LV lead is an alternative.
Objective: Compare the effects of transvenous versus surgical implantation
of the LV lead in CRT.
Methods: We included 100 consecutive patients who had received CRT in
our centre between January 2008 and July 2012 in a retrospective observa-
tional study. Twelve patients who had failed transvenous implantation of LV
lead had a surgical placement.
Results: Population characteristics were a mean age of 66±11 years, 16%
female, New York Heart Association class 2.9±0.5, 45% ischemic cardio-
myopathy, left ventricular ejection fraction (LVEF) 24±7%, QRS width
165±23ms. There were no major difference in preoperative variables between
two groups except sex category (12.5% female in transvenous group versus
42% in surgical group, p=0.022). During a mean follow-up of 508±429 days,
the improvements seen in all variables showed no difference between the
groups. At six months, 77% of patients had improved at least one class of their
dyspnea stage, LVEF improved significantly (24±7% versus 36±10% at
six months).
Conclusions: Surgical placement of LV lead offers similar benefits as
compared with transvenous implantation.
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Background: Electrical cardioversion (EC) is a major treatment of atrial
fibrillation (AF). External EC in patients with persistent AF is inefficient in
10-20% of the patients already pretreated with oral amiodarone. Patients
remain usually in permanent AF.
